A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC)
Clinical trial NCT05262413 · UNKNOWN
Trial details
- NCT number
- NCT05262413
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-28
- Primary completion
- 2023-07-30
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.